Literature DB >> 30075285

The cingulate island sign in patients with dementia with Lewy bodies or Alzheimer's disease: A direct comparison between 18F-FDG PET and 123I-IMP SPECT.

Yuhei Chiba1, Hiroshige Fujishiro2, Eizo Iseki3, Koji Kasanuki4, Kiyoshi Sato5.   

Abstract

The cingulate island sign (CIS) on 18F-fluorodeoxyglucose positron emission tomography (FDG PET); i.e., the relative preservation of mid-posterior cingulate cortex metabolism, is a supportive biomarker in the diagnostic criteria for dementia with Lewy bodies (DLB). Information is lacking, however, regarding the diagnostic value of the CIS on FDG PET or 123I-iodoamphetamine single-photon emission computed tomography (IMP SPECT) for differentiating between mild cognitive impairment (MCI) due to Alzheimer's disease (AD) (MCI-AD) and MCI due to DLB (MCI-DLB). We examined the CIS ratio for nine AD patients, nine DLB patients, eight patients with MCI-AD, and nine patients with MCI-DLB using FDG PET and IMP SPECT. The CIS ratio was calculated as the total count density for the mid-posterior cingulate cortex divided by the total count density for the precuneus and cuneus using the stereotactic extraction estimation method. In the dementia groups, receiver operating characteristic analysis of the CIS ratio showed significant accuracy for differentiating between AD and DLB on both FDG PET and IMP SPECT. In the MCI groups, only the FDG PET-derived CIS ratio displayed significant accuracy for differentiating between AD and DLB. A larger study is needed to replicate these findings.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AD; DLB; Dementia; Early diagnosis; FDG PET; IMP SPECT; Mild cognitive impairment

Year:  2018        PMID: 30075285     DOI: 10.1016/j.neulet.2018.07.040

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  1 in total

1.  Differentiating Mild Cognitive Impairment, Alzheimer's Disease, and Dementia With Lewy Bodies Using Cingulate Island Sign on Perfusion IMP-SPECT.

Authors:  Hidekazu Kanetaka; Soichiro Shimizu; Yuta Inagawa; Daisuke Hirose; Naoto Takenoshita; Hirofumi Sakurai; Haruo Hanyu
Journal:  Front Neurol       Date:  2020-11-19       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.